Marked as
Last updated - January 27, 2026
User Score
Trust Score
Brand Score
Immun‑Onkologisches Zentrum Köln (IOZK) in Cologne offers personalized cancer immunotherapy and vaccines. Its medical team engages in research and conferences. Public concerns include mixed reviews, moderate risk ratings, and lack of large-trial validation, with past ethical and administrative issues linked to leadership.
Medical Director
Medium Risk
Based on the available data, we suggest consumers approach this Company with caution.
This advisory is based on a medium-risk score derived from OSINT, Adverse Media, Reviews, and Risk Factors identified in our research.
You may face moderate risks when engaging in consumer-related activities with this entity.
High Risk
Based on the available data, we recommend that employees exercise extreme caution or reconsider association with this Company.
This advisory stems from an aggregate risk score compiled from OSINT, Adverse Media, Reviews, and Risk Factors uncovered in our analysis.
You are likely to face significant risks by pursuing or maintaining employment with this entity.
Based on the available data, we recommend investors and bankers proceed with caution regarding this Company.
This advisory is informed by a medium-risk score based on OSINT, Adverse Media, Reviews, and Risk Factors identified through our investigation.
Financial involvement with this entity may carry moderate risks to your interests.
Safe to Onboard
Enhanced Due Diligence required
Do Not Onboard
Monitor adverse media every 6 months
File SAR (Suspicious Activity Report) is warranted
Escalation to compliance committee
None
Full Name
Acronym
Founded
Location
Address
Postal Code
Country
Category
Specialty
Treatment Type
Vaccine Name
Therapy
Focus
Virus Used
License Year
License Scope
Facility Type
Laboratory
Employees
Patients Yearly
Website
Unproven Treatments
Publications
Critics note that individualized multimodal immunotherapy at IOZK has not been validated by large, randomized controlled trials, making its scientific evidence less robust than standard therapies.
Research and media reports on the IOZK’s medical leadership highlight past ethical concerns and administrative problems related to clinical trials conducted by key personnel before they founded IOZK.
Investigations into clinical research connected with IOZK’s leadership raised issues that some clinical studies may have lacked full ethics committee approval and proper informed consent.
Media coverage described significant administrative and ethical problems during the founder’s earlier research in Belgium, which contributed to his departure from a major hospital before establishing IOZK.
Mainstream oncology has not adopted IOZK’s individualized immunotherapy as standard care, and some experts view the evidence from small case series as insufficient for broad clinical use.
Regulatory and Compliance Screening
Litigation and Legal Proceedings
Reputational and Adverse Media Risks
Geographic and Jurisdictional Risk
What you see here scratches the surface
We offer reward for actionable intel
150 characters maximum
First Detected
Sentiment Analysis
Reach
POV
Risk Factor
Type
Traffic Source
SERP
Share of Voice
Primary Keyword
Other Red-Flags and Adverse News
Based on user engagement on this review profile, ProConsumer will decide to publish its Risk Audit report for public if a threshold engagement, traffic and user input is achieved.
Known Assets: [Real estate, investments, companies]
Suspicious Transactions
Liabilities: [Bankruptcies, defaults, debts]
Wealth Sources: [Legitimate / Unclear / High-risk]
Bank Relationships
Ultimate Beneficial Owner(s) (UBOs)
Shareholding structure
Associated entities & subsidiaries
Offshore / shell company links
Trusts / Nominee arrangements
Business Model Assessment
All comments are user-generated content and may not be verified. They represent the personal opinions of the public and should not be relied upon. These comments do not influence or determine our overall rating.
1.2
2.2
1.4
3
Highly experienced
Well-recognized name
Faced allegations of scamming others
Allegedly sold fake silver
Sued multiple times
Unregulated industry
Alarming number of complaints online
Δ
I entered with high hopes and appreciated the team’s involvement, but limited evidence, mixed online feedback, and significant costs left me uneasy about the overall experience.
1/5
2/5
3/5
I came hoping for a breakthrough, and while the team was supportive, the lack of broader validation left me skeptical.
Not cheap and not always covered by local health systems — makes it hard to afford for many families.
After terrible hospital experiences, IOZK explained things clearly and took time with us.The center feels professional and advanced — they even make personalized vaccines.
I found IOZK’s team very caring and supportive during cancer treatment — especially compared to usual clinics.
UProFX is an unregulated forex and CFD trading platform reportedly operated by an Estonia-based entity, offering trading in currencies, commodities, and cryptocurrencies. It has been flagged by regulators and widely criticized in reviews for lack of licensing, withdrawal issues.
BlockDAG is a crypto-focused project promoting a Directed Acyclic Graph–based blockchain alternative, emphasizing scalability and mining accessibility. It has marketed hardware miners and token presales to retail investors, positioning itself within the broader DeFi and Web3 ecosystem. Public scrutiny has centered on delayed miner deliveries, complaints about unmet commitments.
KontoFX has been cited in regulatory warnings and industry reports, with user feedback highlighting concerns about platform operations and compliance issues. Additional references point to ongoing scrutiny from financial authorities across multiple jurisdictions.
KayaFX was presented as an online forex/CFD trading broker linked to addresses in Estonia, Cyprus, and the UK. Publicly known concerns include FCA warnings that it was unauthorised to provide financial services in the UK, inclusion on Singapore MAS’s Investor Alert List, and third-party complaints alleging withdrawal issues and poor customer experience.
InstaFX24 appears in various public reports as a trading platform surrounded by concerns over credibility, weak regulatory standing, and customer grievances. Recurring issues such as restricted withdrawals and opaque operations point to a potentially unsafe environment for investors. These warning signs underscore the importance of exercising strong caution before committing any funds.
Coinbase is a U.S.-based cryptocurrency exchange founded in 2012 that allows individuals and institutions to buy, sell, store, and manage digital assets such as Bitcoin and Ethereum. Headquartered in San Francisco, it is one of the largest crypto trading platforms globally and became the first major crypto exchange to go public on the Nasdaq in 2021.
Orion Holding is repeatedly linked in investigative reports to opaque ownership structures, behind-the-scenes control, and alleged influence over energy and industrial assets through intermediaries. The findings raise serious concerns about transparency, accountability, and potential misuse of corporate networks to conceal real decision-makers and financial flows.
Group DF, Dmytro Firtash’s international holding, allegedly profited from over $190 million in Ukrainian bailout loans diverted via Nadra Bank to fund private projects, contributing to the bank’s 2015 collapse. Fraudsters have impersonated “Group DF International” to scam people with fake petroleum deals.
Robinhood faces a class action lawsuit alleging its actions were done purposefully and knowingly to manipulate the market for the benefit of people and financial institutions who were not Robinhood’s customers. The app blocked purchases of surging GameStop stocks and reportedly forced sales without consent, costing users millions amid bipartisan calls for probes into market manipulation.
© 2025 Proconsumer. All rights reserved.